113 related articles for article (PubMed ID: 2128510)
1. Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-dopa in the rat.
Waldmeier PC; De Herdt P; Maitre L
J Neural Transm Suppl; 1990; 32():381-6. PubMed ID: 2128510
[TBL] [Abstract][Full Text] [Related]
2. CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure.
Waldmeier PC; Baumann PA; Feldtrauer JJ; Hauser K; Bittiger H; Bischoff S; von Sprecher G
Naunyn Schmiedebergs Arch Pharmacol; 1990 Sep; 342(3):305-11. PubMed ID: 1980718
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.
Törnwall M; Kaakkola S; Tuomainen P; Kask A; Männistö PT
Br J Pharmacol; 1994 May; 112(1):13-8. PubMed ID: 7518301
[TBL] [Abstract][Full Text] [Related]
4. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
[TBL] [Abstract][Full Text] [Related]
5. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
Männistö PT; Tuomainen P; Tuominen RK
Br J Pharmacol; 1992 Mar; 105(3):569-74. PubMed ID: 1628144
[TBL] [Abstract][Full Text] [Related]
6. Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects.
Bieck PR; Nilsson E; Antonin KH
J Neural Transm Suppl; 1990; 32():387-91. PubMed ID: 2128511
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of the new COMT inhibitor CGP 28,014.
Bieck PR; Antonin KH; Farger G; Nilsson EB; Schmidt EK; Dostert P; Strolin Benedetti M; Waldmeier PC
Neurochem Res; 1993 Nov; 18(11):1163-7. PubMed ID: 8255368
[TBL] [Abstract][Full Text] [Related]
8. Effects of CGP 28014 on the in vivo release and metabolism of dopamine in the rat striatum assessed by brain microdialysis.
Steulet AF; Stöcklin K; Wicki P; Waldmeier P
Neurochem Res; 1993 Nov; 18(11):1131-6. PubMed ID: 8255364
[TBL] [Abstract][Full Text] [Related]
9. Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats.
Brannan T; Martínez-Tica J; Yahr MD
Neurology; 1992 Mar; 42(3 Pt 1):683-5. PubMed ID: 1549240
[TBL] [Abstract][Full Text] [Related]
10. Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase.
Törnwall M; Tuomainen P; Männistö PT
Eur J Pharmacol; 1993 Aug; 239(1-3):39-45. PubMed ID: 8223912
[TBL] [Abstract][Full Text] [Related]
11. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Huang L; Deng M; Zhang S; Fang Y; Li L
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
[TBL] [Abstract][Full Text] [Related]
12. Effect of 3',4'-dihydroxy-2-methyl-propriophenone (U-0521) on catechol-O-methyltransferase activity and on DOPA accumulation in rat red blood cells and corpus striatum.
Reches A; Jiang D; Fahn S
Biochem Pharmacol; 1982 Nov; 31(21):3415-8. PubMed ID: 7150363
[TBL] [Abstract][Full Text] [Related]
13. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
Brannan T; Prikhojan A; Yahr MD
J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo.
Waldmeier PC; Buchle AM; Steulet AF
Biochem Pharmacol; 1993 Jun; 45(12):2417-24. PubMed ID: 7687131
[TBL] [Abstract][Full Text] [Related]
15. Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).
Soares-da-Silva P; Vieira-Coelho MA; Parada A
Pharmacol Toxicol; 2003 Jun; 92(6):272-8. PubMed ID: 12787259
[TBL] [Abstract][Full Text] [Related]
16. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.
Kaakkola S; Wurtman RJ
J Neurochem; 1993 Jan; 60(1):137-44. PubMed ID: 8417137
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.
Nissinen E; Lindén IB; Schultz E; Pohto P
Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep; 346(3):262-6. PubMed ID: 1407012
[TBL] [Abstract][Full Text] [Related]
18. COMT inhibitors and metabolism of fluorodopa enantiomers in aggregating cell cultures.
Wiese C; Cogoli-Greuter M; Weinreich R; Winterhalter KH
Naunyn Schmiedebergs Arch Pharmacol; 1993 Dec; 348(6):582-5. PubMed ID: 8133902
[TBL] [Abstract][Full Text] [Related]
19. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
Napolitano A; Zürcher G; Da Prada M
Eur J Pharmacol; 1995 Feb; 273(3):215-21. PubMed ID: 7737328
[TBL] [Abstract][Full Text] [Related]
20. Catechol-O-methyltransferase inhibition by U-0521 increases striatal utilization of levodopa.
Reches A; Jiang D; Fahn S
Naunyn Schmiedebergs Arch Pharmacol; 1982 Jul; 320(1):34-7. PubMed ID: 7121609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
